Mirador Therapeutics Secures $150M in Series A Funding to Advance Precision Medicine Innovations

Avenzo Therapeutics is thrilled to announce that it has successfully raised $150 million in its latest funding round, further solidifying its position as a pioneer in the field of precision medicine. Established in 2024 and based in the vibrant city of San Diego, CA, Avenzo is committed to revolutionizing the treatment landscape for patients suffering from chronic immune-mediated inflammatory and fibrotic diseases. The company's innovative Mirador360™ precision development engine capitalizes on the latest advancements in human genetics and cutting-edge data science to expedite the discovery and development of life-changing therapies. With this new capital infusion, Avenzo Therapeutics plans to enhance its research and development efforts, accelerating the timeline for bringing potent new medicines to the market. This funding round, which adds to the impressive total of over $400 million raised from top-tier life sciences investors, will enable the company to expand its pipeline and further refine its precision medicine approach. The team at Avenzo is passionate about improving patient outcomes and addressing unmet medical needs, and this investment represents a significant milestone in the company's journey. As they continue to innovate and push the boundaries of what is possible in immunology and inflammation, Avenzo Therapeutics remains dedicated to delivering targeted, effective treatments that can provide hope and relief for those affected by chronic conditions.